Publications

  1. Humeniuk MS, Gertz MA, Lacy MQ, Kyle RA, Witzig TE, Kumar SK, Kapoor P, Lust JA, Hayman SR, Buadi FK, Rajkumar SV, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Leung N, Dispenzieri A. Outcomes of patients with POEMS syndrome treated initially with radiation. Blood. 2013 May 22. [Epub ahead of print] 2325718
    View PubMed
  2. Greenberg AJ, Cousin M, Kumar S, Ketterling RP, Knudson RA, Larson D, Colby C, Scott C, Vachon CM, Vincent Rajkumar S. Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma. Eur J Haematol. 2013 May 06. [Epub ahead of print] 2321941
    View PubMed
  3. Kourelis TV, Gertz M, Zent C, Lacy M, Kyle R, Kapoor P, Zeldenrust S, Buadi F, Witzig T, Hayman S, Lust J, Russell S, Lin Y, Rajkumar VS, Kumar S, Leung N, Dingli D, Dispenzieri A. Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2013 May; 88(5):375-8. Epub 2013 Mar 19. 2311176
    View PubMed
  4. Dispenzieri A, Seenithamby K, Lacy MQ, Kumar SK, Buadi FK, Hayman SR, Dingli D, Litzow MR, Gastineau DA, Inwards DJ, Micallef IN, Ansell SM, Johnston PB, Porrata LF, Patnaik MM, Hogan WJ, Gertz MA. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. Bone Marrow Transplant. 2013 Apr 22. [Epub ahead of print] 2318465
    View PubMed
  5. Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia. 2013 Apr; 27(4):941-6. Epub 2012 Oct 16. 2285799
    View PubMed
  6. Kyle RA, Therneau TM, Dispenzieri A, Kumar S, Benson JT, Larson DR, Melton LJ 3rd, Rajkumar SV. Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):184-6. Epub 2013 Mar 13. 2311150
    View PubMed
  7. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart K, Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clin Proc. 2013 Apr; 88(4):360-76. 2314135
    View PubMed
  8. Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Dingli D, Leung N, Hogan WJ, Buadi FK, Hayman SR. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2013 Apr; 48(4):557-61. Epub 2012 Sep 10. 2269956
    View PubMed
  9. Gonsalves WI, Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Hogan WJ, Kumar SK. Second auto-SCT for treatment of relapsed multiple myeloma. Bone Marrow Transplant. 2013 Apr; 48(4):568-73. Epub 2012 Sep 24. 2272608
    View PubMed
  10. Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D, Ketterling RP, Lust JA, Kyle RA, Kumar SK. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia. 2013 Mar 21. [Epub ahead of print] 2311840
    View PubMed
  11. Kumar SK. Digging deeper with allogeneic transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2013 Mar; 19(3):335-6. Epub 2013 Jan 02. 2294181
    View PubMed
  12. Micallef IN, Sinha S, Gastineau DA, Wolf R, Inwards DJ, Gertz MA, Hayman SR, Hogan WJ, Johnston PB, Lacy MQ, Ansell SM, Buadi F, Dingli D, Dispenzieri A, Litzow MR, Porrata LF, Winters JL, Kumar S. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant. 2013 Jan; 19(1):87-93. Epub 2012 Aug 23. 2266553
    View PubMed
  13. Leung N, Glavey SV, Kumar S, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Gertz MA. A detailed evaluation of the current renal response criteria in AL amyloidosis: Is it time for a revision? Haematologica. 2013; 98(6):988-92. 2329825
  14. Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant. 2013; 19(5):760-6. 2320758
  15. Fernandez De Larrea C, Kyle RA, Durie BGM, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, Leleu X, Dimopoulos Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013; 27(4):780-91. 2320773
  16. Painuly U, Kumar S. Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. Clin Med Insights Oncol. 2013; 7:53-73. Epub 2013 Feb 28. 2311211
    View PubMed
  17. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schonland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012 Dec 20; 30(36):4541-9. Epub 2012 Oct 22. 2279324
    View PubMed
  18. Cordes S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Kumar SK, Hogan WJ, Gertz MA. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer. 2012 Dec 15; 118(24):6105-9. Epub 2012 Jun 15. 2252556
    View PubMed
  19. Leung N, Gertz M, Kyle RA, Fervenza FC, Irazabal MV, Eirin A, Kumar S, Cha SS, Rajkumar SV, Lacy MQ, Zeldenrust SR, Buadi FK, Hayman SR, Nasr SH, Sethi S, Ramirez-Alvarado M, Witzig TE, Herrmann SM, Dispenzieri A. Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. Clin J Am Soc Nephrol. 2012 Dec; 7(12):1964-8. Epub 2012 Sep 27. 2273666
    View PubMed
  20. Therneau TM, Kyle RA, Melton LJ 3rd, Larson DR, Benson JT, Colby CL, Dispenzieri A, Kumar S, Katzmann JA, Cerhan JR, Rajkumar SV. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc. 2012 Nov; 87(11):1071-9. Epub 2012 Aug 07. 2263966
    View PubMed
  21. Bleeker JS, Gertz MA, Pellikka PA, Larson DR, Buadi F, Dingli D, Dispenzieri A, Hayman SR, Hogan W, Kumar S, Rajkumar SV, Lacy MQ. Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation. Eur J Haematol. 2012 Sep; 89(3):228-35. Epub 2012 Jul 13. 2257703
    View PubMed
  22. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, Kumar S, Rajkumar SV, Carpten JD, Barrett M, Fonseca R, Stewart AK, Bergsagel PL. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012 Aug 2; 120(5):1067-76. Epub 2012 Apr 12. 2264431
    View PubMed
  23. D'Souza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S, Dingli D, Zeldenrust S, Kyle R, Ansell S, Inwards D, Johnston P, Micallef I, Porrata L, Litzow M, Gastineau D, Hogan W, Dispenzieri A. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood. 2012 Jul 5; 120(1):56-62. Epub 2012 May 18. 2247749
    View PubMed
  24. Warsame R, Gertz MA, Lacy MQ, Kyle RA, Buadi F, Dingli D, Greipp PR, Hayman SR, Kumar SK, Lust JA, Russell SJ, Witzig TE, Mikhael J, Leung N, Zeldenrust SR, Rajkumar SV, Dispenzieri A. Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol. 2012 Jul; 87(7):647-51. Epub 2012 May 02. 2242189
    View PubMed
  25. Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, Dingli D, Zeldenrust SR, Mikhael JR, Hall R, Rajkumar SV, Reeder C, Fonseca R, Bergsagel PL, Stewart AK, Roy V, Witzig TE, Lust JA, Russell SJ, Gertz MA, Lacy MQ. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012 Jun 7; 119(23):5397-404. Epub 2012 Apr 04. 2238866
    View PubMed
  26. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Therneau TM, Colby CL, Clark RJ, Mead GP, Kumar S, Melton LJ 3rd, Rajkumar SV. Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. Mayo Clin Proc. 2012 Jun; 87(6):517-23. 2252594
    View PubMed
  27. Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, Lust JA, Fonseca R, Russell SJ, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012 May 24; 119(21):4860-7. Epub 2012 Apr 13. 2238853
    View PubMed
  28. Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012 May 10; 119(19):4375-82. Epub 2012 Mar 15. 2244808
    View PubMed
  29. Kyle RA, Benson JT, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Melton LJ 3rd, Rajkumar SV. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood. 2012 May 10; 119(19):4462-6. Epub 2012 Mar 26. 2235355
    View PubMed
  30. Greenberg AJ, Rajkumar SV, Larson DR, Dispenzieri A, Therneau TM, Colby CL, Phelps TK, Kumar SK, Katzmann JA, Kyle RA, Slager SL, Vachon CM. Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma. Br J Haematol. 2012 May; 157(4):472-5. 2242623
    View PubMed
  31. Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang MJ, Li P, Berenson JR, Bird JM, Dispenzieri A, Gajewski JL, Gale RP, Holmberg L, Kumar S, Kyle RA, Lazarus HM, Lonial S, Mikhael J, Milone GA, Munker R, Nath R, Saccaro S, To LB, Vogl DT, Wirk B, Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia. 2012 May; 26(5):1091-7. Epub 2011 Nov 01. 2226314
    View PubMed
  32. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012 Mar 20; 30(9):989-95. Epub 2012 Feb 13. 2224219
    View PubMed
  33. Kumar SK, Lacy MQ, Dispenzieri A, Buadi FK, Hayman SR, Dingli D, Gay F, Sinha S, Leung N, Hogan W, Rajkumar SV, Gertz MA. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer. 2012 Mar 15; 118(6):1585-92. Epub 2011 Aug 25. 2199717
    View PubMed
  34. Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Hayman SR, Buadi FK, Dingli D, Knudson RA, Greenberg A, Russell SJ, Zeldenrust SR, Lust JA, Kyle RA, Bergsagel L, Rajkumar SV. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012 Mar 1; 119(9):2100-5. Epub 2012 Jan 10. 2216586
    View PubMed
  35. Eirin A, Irazabal MV, Gertz MA, Dispenzieri A, Lacy MQ, Kumar S, Sethi S, Nasr SH, Cornell LD, Fidler ME, Fervenza FC, Leung N. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. Nephrol Dial Transplant. 2012 Mar; 27(3):1097-101. Epub 2011 Nov 07. 2204896
    View PubMed
  36. Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Halling T, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA, Kumar S. Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. Am J Hematol. 2012 Mar; 87(3):277-83. Epub 2011 Dec 21. 2235411
    View PubMed
  37. Kumar S. Risk of early death in multiple myeloma. Clin Adv Hematol Oncol. 2012 Mar; 10(3):172-4. 2235892
    View PubMed
  38. Bianchi G, Kumar S, Ghobrial IM, Roccaro AM. Cell Trafficking in Multiple Myeloma. Open J Hematol. 2012 Feb 21; 3(Suppl 1). 2329980
    View PubMed
  39. Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, Hogan WJ, Leung N, Grogan M, Gertz MA. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood. 2012 Feb 2; 119(5):1117-22. Epub 2011 Dec 06. 2209936
    View PubMed
  40. Ramakrishnan V, Ansell S, Haug J, Grote D, Kimlinger T, Stenson M, Timm M, Wellik L, Halling T, Rajkumar SV, Kumar S. MRK003, a gamma-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. Leukemia. 2012 Feb; 26(2):340-8. Epub 2011 Aug 9. 2228622
    View PubMed
  41. Khan ML, Reeder CB, Kumar SK, Lacy MQ, Reece DE, Dispenzieri A, Gertz MA, Greipp P, Hayman S, Zeldenhurst S, Dingli D, Lust J, Russell S, Laumann KM, Mikhael JR, Leif Bergsagel P, Fonseca R, Vincent Rajkumar S, Keith Stewart A. A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. Br J Haematol. 2012 Feb; 156(3):326-33. Epub 2011 Nov 23. 2208742
    View PubMed
  42. Gertz MA, Buadi FK, Hayman SR, Dingli D, Dispenzieri A, Greipp PR, Kumar SK, Lacy MQ, Lust JA, Leung N, Rajkumar SV, Russell SJ, Zeldenrust SR, Mikhael JR, Roy V, Kyle RA. Immunoglobulin D amyloidosis: a distinct entity. Blood. 2012 Jan 5; 119(1):44-8. Epub 2011 Nov 07. 2204946
    View PubMed
  43. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Blade J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012 Jan; 26(1):149-57. Epub 2011 Jul 29. 2247929
    View PubMed
  44. Ozsan GH, Micallef IN, Dispenzieri A, Kumar S, Lacy MQ, Dingli D, Hayman SR, Buadi FK, Wolf RC, Gastineau DA, Hogan WJ, Gertz MA. Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma. Am J Hematol. 2012 Jan; 87(1):1-4. Epub 2011 Sep 29. 2216672
    View PubMed
  45. Irazabal MV, Eirin A, Gertz MA, Dispenzieri A, Kumar S, Buadi FK, Lacy MQ, Hayman SR, Dingli D, Hogan WJ, Gastineau DA, Glavey SV, Amer H, Leung N. Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis. Am J Hematol. 2012 Jan; 87(1):51-4. Epub 2011 Nov 11. 2206842
    View PubMed
  46. Painuly U, Kumar S. Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. Clinical Medicine Insights: Oncology. 2012; 7:53-73. 2313471
  47. Ramakrishnan V, Kimlinger T, Haug J, Painuly U, Wellik L, Halling T, Rajkumar SV, Kumar S. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway. PLoS One. 2012; 7(11):e50005. Epub 2012 Nov 21. 2285812
    View PubMed
  48. Ng AC, Khosla S, Charatcharoenwitthaya N, Kumar SK, Achenbach SJ, Holets MF, McCready LK, Melton LJ 3rd, Kyle RA, Rajkumar SV, Drake MT. Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1alpha levels in patients with MGUS. Blood. 2011 Dec 15; 118(25):6529-34. Epub 2011 Oct 31. 2203569
    View PubMed
  49. Jacobus SJ, Kumar S, Uno H, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Williams ME, Siegel DS, Greipp PR, Rajkumar SV, Fonseca R. Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. Br J Haematol. 2011 Nov; 155(3):340-8. Epub 2011 Sep 09. 2189367
    View PubMed
  50. Kapoor P, Thenappan T, Singh E, Kumar S, Greipp PR. Cardiac amyloidosis: a practical approach to diagnosis and management. Am J Med. 2011 Nov; 124(11):1006-15. 2201846
    View PubMed
  51. D'Souza A, Hayman SR, Buadi F, Mauermann M, Lacy MQ, Gertz MA, Kyle RA, Kumar S, Greipp PR, Lust JA, Russell SJ, Zeldenrust S, Dingli D, Witzig TE, Rajkumar SV, Dispenzieri A. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood. 2011 Oct 27; 118(17):4663-5. Epub 2011 Aug 31. 2187822
    View PubMed
  52. Kumar SK, Uno H, Jacobus SJ, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Haug JL, Siegel DS, Greipp PR, Fonseca R, Rajkumar SV. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2011 Oct 20; 118(16):4359-62. Epub 2011 Aug 22. 2208766
    View PubMed
  53. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011 Sep 15; 118(11):2970-5. Epub 2011 Jun 20. 2190630
    View PubMed
  54. Wadhera RK, Kyle RA, Larson DR, Dispenzieri A, Kumar S, Lazarus HM, Rajkumar SV. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood. 2011 Sep 15; 118(11):2985-7. Epub 2011 Jul 15. 2178067
    View PubMed
  55. Kumar SK. Myeloma ASH 2010 highlights. Am J Hematol. 2011 Sep; 86(9):820-3. Epub 2011 Jul 28. 2179341
    View PubMed
  56. Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan A, Maiolino A, Wirk B, Weiss B, Freytes CO, Vogl DT, Vesole DH, Lazarus HM, Meehan KR, Hamadani M, Lill M, Callander NS, Majhail NS, Wiernik PH, Nath R, Kamble RT, Vij R, Kyle RA, Gale Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood. 2011 Aug 18; 118(7):1979-88. Epub 2011 Jun 20. 2172193
    View PubMed
  57. Madan S, Lacy MQ, Dispenzieri A, Gertz MA, Buadi F, Hayman SR, Detweiler-Short K, Dingli D, Zeldenrust S, Lust J, Greipp PR, Rajkumar SV, Kumar S. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood. 2011 Aug 18; 118(7):1763-5. Epub 2011 Jun 14. 2170029
    View PubMed
  58. Kumar SK, Lacy MQ, Hayman SR, Stewart K, Buadi FK, Allred J, Laumann K, Greipp PR, Lust JA, Gertz MA, Zeldenrust SR, Bergsagel PL, Reeder CB, Witzig TE, Fonseca R, Russell SJ, Mikhael JR, Dingli D, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol. 2011 Aug; 86(8):640-5. Epub 2011 May 31. 2167780
    View PubMed
  59. Gertz MA, Gastineau DA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Dingli D, Leung N, Wolf RC, Hogan WJ, Buadi FK. SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization. Bone Marrow Transplant. 2011 Jul; 46(7):956-61. Epub 2010 Oct 25. 2179599
    View PubMed
  60. Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Buadi FK, Dingli D, Leung N, Hogan WJ, Hayman SR. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant. 2011 Jul; 46(7):970-5. Epub 2010 Oct 11. 2118567
    View PubMed
  61. Herrmann SM, Gertz MA, Stegall MD, Dispenzieri A, Cosio FC, Kumar S, Lacy MQ, Dean PG, Prieto M, Zeldenrust SR, Buadi FK, Russell SJ, Nyberg SL, Hayman SR, Dingli D, Fervenza FC, Leung N. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant. 2011 Jun; 26(6):2032-6. Epub 2011 May 04. 2163981
    View PubMed
  62. Kumar S. Treatment of newly diagnosed multiple myeloma in transplant-eligible patients. Curr Hematol Malig Rep. 2011 Jun; 6(2):104-12. 2151560
    View PubMed
  63. Patel B, Dey A, Ghorani E, Kumar S, Malam Y, Rai L, Steele AJ, Thomson J, Wickremasinghe RG, Zhang Y, Castleton AZ, Fielding AK. Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights. Mol Ther. 2011 Jun; 19(6):1034-40. Epub 2011 Mar 22. 2170740
    View PubMed
  64. Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, Dispenzieri A, Winters JL, Kumar S, Rajkumar SV, Kyle RA, Leung N. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011 Jun; 22(6):1129-36. Epub 2011 Apr 21. 2173641
    View PubMed
  65. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksac M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC, Jagannath S, Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011 May 5; 117(18):4701-5. Epub 2011 Feb 03. 2188498
    View PubMed
  66. Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Tan T, Sinha S, Leung N, Kyle RA, Rajkumar SV, Gertz MA. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol. 2011 Mar; 86(3):251-5. Epub 2011 Feb 15. 2147499
    View PubMed
  67. Kyle RA, Dispenzieri A, Kumar S, Larson D, Therneau T, Rajkumar SV. IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenstrom's macroglobulinemia (SWM). Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):74-6. 2165344
    View PubMed
  68. Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK, Short-Detweiler K, Zeldenrust SR, Leung N, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Dispenzieri A. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011 Jan; 86(1):12-8. 2141511
    View PubMed
  69. Siragusa S, Morice W, Gertz MA, Kyle RA, Greipp PR, Lust JA, Witzig TE, Lacy MQ, Zeldenrust SR, Rajkumar SV, Russell SJ, Hayman SR, Buadi F, Kumar SK, Dingli D, Dispenzieri A. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Ann Hematol. 2011 Jan; 90(1):101-6. Epub 2010 Jul 20. 2147662
    View PubMed
  70. Madan S, Kumar S. Current treatment options for elderly patients with multiple myeloma: Clinical impact of novel agents. Therapy. 2011; 8(4):415-29. 2188202
  71. Kumar S, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ, Hayman SR, Buadi FK, Leung N, Zeldenrust SR, Ramirez-Alvarado M, Clark RJ, Kyle RA, Rajkumar SV, Gertz MA. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010 Dec 9; 116(24):5126-9. Epub 2010 Aug 26. 2112322
    View PubMed
  72. Reece DE, Vesole DH, Shrestha S, Zhang MJ, Perez WS, Dispenzieri A, Milone GA, Abidi M, Atkins H, Bashey A, Bredeson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, Kumar S, Kyle RA, Lazarus HM, McCarthy PL, Pavlovsky S, Roy V, Weisdorf Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study. Clin Lymphoma Myeloma Leuk. 2010 Dec; 10(6):458-63. 2143969
    View PubMed
  73. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Dingli D, Ansell SM, Gastineau DA, Inwards DJ, Johnston PB, Litzow MR, Micallef IN, Porrata LF, Leung N, Hogan WJ, Buadi FK. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma. 2010 Dec; 51(12):2181-7. Epub 2010 Oct 20. 2136163
    View PubMed
  74. Detweiler-Short K, Hayman S, Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Zeldenrust SR, Russell SJ, Lust JA, Kyle RA, Greipp PR, Witzig TE, Vincent Rajkumar S. Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. Am J Hematol. 2010 Oct; 85(10):737-40. 2111499
    View PubMed
  75. Kapoor P, Greipp PT, Schaefer EW, Mandrekar SJ, Kamal AH, Gonzalez-Paz NC, Kumar S, Greipp PR. Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience. Mayo Clin Proc. 2010 Oct; 85(10):905-12. Epub 2010 Jul 15. 2106707
    View PubMed
  76. Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S, Buadi F, Zeldenrust S, Leung N, Detweiler-Short K, Lust JA, Russell SJ, Kyle RA, Gertz MA. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol. 2010 Oct; 85(10):757-9. 2116202
    View PubMed
  77. Bianchi G, Kyle RA, Colby CL, Larson DR, Kumar S, Katzmann JA, Dispenzieri A, Therneau TM, Cerhan JR, Melton LJ 3rd, Rajkumar SV. Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood. 2010 Sep 23; 116(12):2019-25; quiz 2197. Epub 2010 May 21. 2002088
    View PubMed
  78. Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol. 2010 Sep; 85(9):664-9. 2106660
    View PubMed
  79. Ramakrishnan V, Kimlinger T, Haug J, Timm M, Wellik L, Halling T, Pardanani A, Tefferi A, Rajkumar SV, Kumar S. TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. Am J Hematol. 2010 Sep; 85(9):675-86. 2115547
    View PubMed
  80. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, Kumar SK, Lacy MQ, Lust JA, Markovic SN, Micallef IN, Nowakowski GS, Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010 Sep; 85(9):824-33. Epub 2010 Aug 11. 2114937
    View PubMed
  81. Gay F, Vincent Rajkumar S, Falco P, Kumar S, Dispenzieri A, Petrucci MT, Gertz MA, Boccadoro M, Keith Stewart A, Palumbo A. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma. Eur J Haematol. 2010 Sep; 85(3):200-8. Epub 2010 May 08. 2203453
    View PubMed
  82. Kumar S, Kimlinger T, Morice W. Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol. 2010 Sep; 23(3):433-51. 2125573
    View PubMed
  83. Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia. 2010 Jul; 24(7):1350-6. Epub 2010 May 27. 2002040
    View PubMed
  84. Pavletic SZ, Kumar S, Mohty M, de Lima M, Foran JM, Pasquini M, Zhang MJ, Giralt S, Bishop MR, Weisdorf D. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant. 2010 Jul; 16(7):871-90. Epub 2010 Apr 24. 2155554
    View PubMed
  85. Kumar S. Treatment of newly diagnosed multiple myeloma: advances in current therapy. Med Oncol. 2010 Jun; 27 Suppl 1:S14-24. Epub 2009 Dec 25. 1978260
    View PubMed
  86. Kapoor P, Fonseca R, Rajkumar SV, Sinha S, Gertz MA, Stewart AK, Bergsagel PL, Lacy MQ, Dingli DD, Ketterling RP, Buadi F, Kyle RA, Witzig TE, Greipp PR, Dispenzieri A, Kumar S. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc. 2010 Jun; 85(6):532-7. 2002025
    View PubMed
  87. Stankowski-Drengler T, Gertz MA, Katzmann JA, Lacy MQ, Kumar S, Leung N, Hayman SR, Buadi F, Kyle RA, Rajkumar SV, Dispenzieri A. Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome. Am J Hematol. 2010 Jun; 85(6):431-4. 2002010
    View PubMed
  88. Dispenzieri A, Wiseman GA, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, Laumann KM, Allred J, Geyer SM, Litzow MR, Gastineau DA, Inwards DJ, Micallef IN, Ansell SM, Porrata L, Elliott MA, Johnston PB, Hogan WJ, Gertz MA. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Am J Hematol. 2010 Jun; 85(6):409-13. 2002011
    View PubMed
  89. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ 3rd, Colby CL, Therneau TM, Clark R, Kumar SK, Bradwell A, Fonseca R, Jelinek DF, Rajkumar SV. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010 May 15; 375(9727):1721-8. 2002156
    View PubMed
  90. Kumar S. Multiple myeloma - current issues and controversies. Cancer Treat Rev. 2010 May; 36 Suppl 2:S3-11. 2002056
    View PubMed
  91. Lorenz EC, Sethi S, Poshusta TL, Ramirez-Alvarado M, Kumar S, Lager DJ, Fervenza FC, Leung N. Renal failure due to combined cast nephropathy, amyloidosis and light-chain deposition disease. Nephrol Dial Transplant. 2010 Apr; 25(4):1340-3. Epub 2010 Jan 08. 1980511
    View PubMed
  92. Gertz MA, Kumar S, Lacy MQ, Dispenzieri A, Dingli D, Hayman SR, Buadi FK, Hogan WJ. Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood. 2010 Mar 25; 115(12):2348-53; quiz 2560. Epub 2010 Jan 20. 1982504
    View PubMed
  93. Dingli D, Tan TS, Kumar SK, Buadi FK, Dispenzieri A, Hayman SR, Lacy MQ, Gastineau DA, Hogan WJ, Gertz MA. Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis. Neurology. 2010 Mar 16; 74(11):913-8. 1992901
    View PubMed
  94. Kumar S, Rajkumar SV. ASH 2009 meeting report-Top 10 clinically oriented abstracts in multiple myeloma. Am J Hematol. 2010 Mar; 85(3):210-3. 1985079
    View PubMed
  95. Madan S, Dispenzieri A, Lacy MQ, Buadi F, Hayman SR, Zeldenrust SR, Rajkumar SV, Gertz MA, Kumar SK. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc. 2010 Mar; 85(3):232-8. 1990535
    View PubMed
  96. Sadek I, Kapoor P, Gertz MA, Kumar S. An unusual neurological complication of light chain amyloidosis. Br J Haematol. 2010 Mar; 148(6):816. Epub 2009 Sep 16. 1962111
    View PubMed
  97. Sinha S, Rajkumar SV, Lacy MQ, Hayman SR, Buadi FK, Dispenzieri A, Dingli D, Kyle RA, Gertz MA, Kumar S. Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma. Br J Haematol. 2010 Mar; 148(6):853-8. Epub 2009 Dec 03. 2124105
    View PubMed
  98. Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Rajkumar SV. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 2010 Feb 18; 115(7):1343-50. Epub 2009 Dec 11. 1977215
    View PubMed
  99. Schaefer EW, Kumar S, Dispenzieri A, Allred JB, Gertz MA, Lacy MQ, Rajkumar SV, Mandrekar SJ. Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myeloma. Cancer. 2010 Feb 1; 116(3):640-6. 1974148
    View PubMed
  100. Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4. 1999989
    View PubMed
  101. Lacy MQ, Mandrekar S, Dispenzieri A, Hayman S, Kumar S, Buadi F, Dingli D, Litzow M, Wettstein P, Padley D, Kabat B, Gastineau D, Rajkumar SV, Gertz MA. Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am J Hematol. 2009 Dec; 84(12):799-802. 1971329
    View PubMed
  102. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, Short KE, Stewart AK, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Bergsagel PL. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009 Dec; 84(12):1095-110. 1975564
    View PubMed
  103. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009 Oct 20; 27(30):5008-14. Epub 2009 Aug 31. 1959998
    View PubMed
  104. Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, Bianchi G, Podar K, Tai YT, Mitsiades C, Raje N, Jaye DL, Kumar SK, Richardson P, Munshi N, Anderson KC. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009 Oct 6; 16(4):309-23. 1971868
    View PubMed
  105. Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood. 2009 Oct 1; 114(14):2926-35. Epub 2009 Jul 29. 1954792
    View PubMed
  106. Gertz MA, Leung N, Lacy MQ, Dispenzieri A, Zeldenrust SR, Hayman SR, Buadi FK, Dingli D, Greipp PR, Kumar SK, Lust JA, Rajkumar SV, Russell SJ, Witzig TE. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant. 2009 Oct; 24(10):3132-7. Epub 2009 Apr 29. 1963369
    View PubMed
  107. Chee CE, Kumar S, Larson DR, Kyle RA, Dispenzieri A, Gertz MA, Colby CL, Rajkumar SV. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood. 2009 Sep 24; 114(13):2617-8. Epub 2009 Jul 29. 1954791
    View PubMed
  108. Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S, Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H, Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009 Aug 27; 114(9):1729-35. Epub 2009 Jun 26. 2155688
    View PubMed
  109. Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR, Colby CL, Phelps TK, Dispenzieri A, Kumar SK, Katzmann JA, Rajkumar SV. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood. 2009 Jul 23; 114(4):785-90. Epub 2009 Jan 29. 1920506
    View PubMed
  110. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Stewart AK, Kyle RA, Greipp PR, Rajkumar SV. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009 Jul 16; 114(3):518-21. Epub 2009 Mar 26. 1933658
    View PubMed
  111. Chen C, Reece DE, Siegel D, Niesvizky R, Boccia RV, Stadtmauer EA, Abonour R, Richardson P, Matous J, Kumar S, Bahlis NJ, Alsina M, Vescio R, Coutre SE, Pietronigro D, Knight RD, Zeldis JB, Rajkumar V. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol. 2009 Jul; 146(2):164-70. Epub 2009 May 26. 1965479
    View PubMed
  112. Peng KW, Dogan A, Vrana J, Liu C, Ong HT, Kumar S, Dispenzieri A, Dietz AB, Russell SJ. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Am J Hematol. 2009 Jul; 84(7):401-7. 1946889
    View PubMed
  113. Ng AC, Kumar SK, Rajkumar SV, Drake MT. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am J Hematol. 2009 Jul; 84(7):397-400. 1940716
    View PubMed
  114. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009 May 28; 113(22):5412-7. Epub 2009 Jan 29. 1962513
    View PubMed
  115. Costa LJ, Kumar S, Dispenzieri A, Hayman SE, Buadi FK, Dingli D, Litzow MR, Gertz MA, Lacy MQ. Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leuk Lymphoma. 2009 May; 50(5):781-7. 1962574
    View PubMed
  116. Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Gastineau DA, Winters JL, Litzow MR. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2009 Apr; 43(8):619-25. Epub 2008 Nov 10. 1915404
    View PubMed
  117. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, Kumar S, Hayman S, Buadi F, Kyle RA, Greipp PR, Lust JA, Russell S, Rajkumar SV, Fonseca R, Dispenzieri A. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica. 2009 Mar; 94(3):380-6. Epub 2009 Feb 11. 1923930
    View PubMed
  118. Kumar S. Stem cell transplantation for multiple myeloma. Curr Opin Oncol. 2009 Mar; 21(2):162-70. 1949861
    View PubMed
  119. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, Kumar S, Hayman SR, Russell SJ, Buadi FK, Geyer SM, Campbell ME, Kyle RA, Rajkumar SV, Greipp PR, Kline MP, Xiong Y, Moon-Tasson LL, Donovan KA. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc. 2009 Feb; 84(2):114-22. 1920497
    View PubMed
  120. Madan S, Kumar S. Extramedullary disease in multiple myeloma. Clin. adv. hematol. oncol. 2009; 7(12):802-4. 1988260
    View PubMed
  121. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Kumar S, Kyle RA, Fonseca R, Greipp PR, Lust JA, Rajkumar VS, Hayman SR, Buadi F, Russell SJ, Zeldenrust SR, Dispenzieri A. A novel report of cig-FISH and cytogenetics in POEMS syndrome. Am J Hematol. 2008 Nov; 83(11):840-1. 1915565
    View PubMed
  122. Snozek CL, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM, Melton LJ 3rd, Kumar S, Greipp PR, Clark RJ, Rajkumar SV. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia. 2008 Oct; 22(10):1933-7. Epub 2008 Jul 03. 1906549
    View PubMed
  123. Kumar S, Perez WS, Zhang MJ, Ballen K, Bashey A, To LB, Bredeson CN, Cairo MS, Elfenbein GJ, Freytes CO, Gale RP, Gibson J, Kyle RA, Lacy MQ, Lazarus HM, McCarthy PL, Milone GA, Moreb JS, Pavlovsky S, Reece DE, Vesole DH, Wiernik PH, Hari P. Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant. 2008 Oct; 14(10):1134-40. 1906506
    View PubMed
  124. Gertz MA, Ansell SM, Dingli D, Dispenzieri A, Buadi FK, Elliott MA, Gastineau DA, Hayman SR, Hogan WJ, Inwards DJ, Johnston PB, Kumar S, Lacy MQ, Leung N, Micallef IN, Porrata LF, Schafer BA, Wolf RC, Litzow MR. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc. 2008 Oct; 83(10):1131-8. 1904604
    View PubMed
  125. Kumar S, Rajkumar SV. Many facets of bortezomib resistance/susceptibility. Blood. 2008 Sep 15; 112(6):2177-8. 1915679
    View PubMed
  126. Kumar S, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, Litzow MR, Gertz MA. Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant. 2008 Sep; 42(6):413-20. Epub 2008 Jun 30. 1915832
    View PubMed
  127. Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Kyle RA, Rajkumar SV, Edwards BS, Rodeheffer RJ, Frantz RP, Kushwaha SS, Clavell AL, Dearani JA, Sundt TM, Daly RC, McGregor CG, Gastineau DA, Litzow MR, Gertz MA. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. J Heart Lung Transplant. 2008 Aug; 27(8):823-9. Epub 2008 Jul 03. 1904685
    View PubMed
  128. Kumar S, Dingli D, Dispenzieri A, Lacy M, Hayman SR, Buadi F, Rajkumar S, Litzow M, Gertz M. Impact of additional cytoreduction following autologous SCT in multiple myeloma. Bone Marrow Transplant. 2008 Aug; 42(4):259-64. Epub 2008 Jun 16. 1902455
    View PubMed
  129. Shaikh A, Habermann TM, Fidler ME, Kumar S, Leung N. Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenstrom's macroglobulinemia. Clin Exp Nephrol. 2008 Aug; 12(4):292-5. Epub 2008 Feb 22. 1900777
    View PubMed
  130. Kumar SK, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Rajkumar SV, Litzow MR, Gertz MA. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. Am J Hematol. 2008 Aug; 83(8):614-7. 1898759
    View PubMed
  131. Wang L, Kumar S, Fridley BL, Kalari KR, Moon I, Pelleymounter LL, Hildebrandt MA, Batzler A, Eckloff BW, Wieben ED, Greipp PR. Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics. Clin Cancer Res. 2008 Jun 1; 14(11):3503-13. 1894727
    View PubMed
  132. Kumar SK, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Rajkumar SV, Litzow MR, Gertz MA. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. Bone Marrow Transplant. 2008 Jun; 41(12):1013-9. Epub 2008 Mar 10. 1902464
    View PubMed
  133. Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, Kumar S, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Hayman SR, Russell SJ, Kyle RA, Winters JL. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008 Jun; 73(11):1282-8. Epub 2008 Apr 02. 1900888
    View PubMed
  134. Ege H, Gertz MA, Markovic SN, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Porrata LF. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. Br J Haematol. 2008 Jun; 141(6):792-8. Epub 2008 Apr 10. 1894792
    View PubMed
  135. Simpson L, Kumar SK, Okuno SH, Schaff HV, Porrata LF, Buckner JC, Moynihan TJ. Malignant primary cardiac tumors: review of a single institution experience. Cancer. 2008 Jun; 112(11):2440-6. 1898803
    View PubMed
  136. Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, Lust JA, Greipp PR, Kumar S. R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. Exp Hematol. 2008 May; 36(5):568-76. Epub 2008 Mar 17. 1898781
    View PubMed
  137. Dispenzieri A, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, Litzow MR, Gastineau DA, Inwards DJ, Elliott MA, Micallef IN, Ansell SM, Hogan WJ, Porrata LF, Johnston PA, Afessa B, Bryce A, Kyle RA, Gertz MA. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. Eur J Haematol. 2008 May; 80(5):397-406. Epub 2008 Jan 23. 1874207
    View PubMed
  138. Kumar S. Role of allogeneic stem cell transplantation in multiple myeloma. Curr Hematol Malig Rep. 2008 Apr; 3(2):99-106. 1997899
    View PubMed
  139. Kumar SK, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Rajkumar SV, Litzow MR, Gertz MA. Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. Br J Haematol. 2008 Apr; 141(2):205-11. Epub 2008 Mar 03. 1883197
    View PubMed
  140. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008 Mar 1; 111(5):2516-20. Epub 2007 Nov 01. 1872155
    View PubMed
  141. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Leung N, Zeldenrust SR, Buadi FK, Kyle RA, Rajkumar SV, Gertz MA. Serum uric acid: novel prognostic factor in primary systemic amyloidosis. Mayo Clin Proc. 2008 Mar; 83(3):297-303. 1872183
    View PubMed
  142. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, Clark RJ, Melton LJ 3rd, Gertz MA, Kumar SK, Fonseca R, Jelinek DF, Rajkumar SV. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008 Jan 15; 111(2):785-9. Epub 2007 Oct 17. 1867670
    View PubMed
  143. Gertz M, Lacy M, Dispenzieri A, Hayman S, Kumar S, Buadi F, Leung N, Litzow M. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma. 2008 Jan; 49(1):36-41. 1872144
    View PubMed
  144. Kumar SK, Hayman SR, Kyle RA. Autologous stem cell transplantation in the elderly including pre- and post-treatment options. Bone Marrow Transplant. 2007 Dec; 40(12):1115-21. Epub 2007 Aug 06. 1858988
    View PubMed
  145. Dingli D, Pacheco JM, Nowakowski GS, Kumar SK, Dispenzieri A, Hayman SR, Lacy MQ, Gastineau DA, Gertz MA. Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol. 2007 Nov 1; 25(31):4933-7. 1853398
    View PubMed
  146. Kumar S. Lenalidomide with or without dexamethasone for relapsed or refractory multiple myleoma. Am J Hematol Oncol. 2007 Nov; 6(11):644-5, 650. 1894610
    View PubMed
  147. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Leung N, Gastineau DA. Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL). Bone Marrow Transplant. 2007 Nov; 40(10):989-93. Epub 2007 Sep 10. 1848995
    View PubMed
  148. Meng XW, Lee SH, Dai H, Loegering D, Yu C, Flatten K, Schneider P, Dai NT, Kumar SK, Smith BD, Karp JE, Adjei AA, Kaufmann SH. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem. 2007 Oct 12; 282(41):29831-46. Epub 2007 Aug 13. 1846371
    View PubMed
  149. Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Bergsagel PL, Stewart AK, Rajkumar SV. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc. 2007 Oct; 82(10):1179-84. 1844441
    View PubMed
  150. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Leung N, Gastineau DA. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica. 2007 Oct; 92(10):1415-8. 1844518
    View PubMed
  151. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, Litzow MR, Fonseca R, Roy V, Rajkumar SV, Gertz MA. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007 Sep; 21(9):2035-42. Epub 2007 Jun 21. 1841419
    View PubMed
  152. Morice WG, Hanson CA, Kumar S, Frederick LA, Lesnick CE, Greipp PR. Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. Leukemia. 2007 Sep; 21(9):2043-6. Epub 2007 Apr 26. 1841420
    View PubMed
  153. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007 Aug; 12(2):131-44. 1841644
    View PubMed
  154. Dingli D, Pacheco JM, Dispenzieri A, Hayman SR, Kumar SK, Lacy MQ, Gastineau DA, Gertz MA. Serum M-spike and transplant outcome in patients with multiple myeloma. Cancer Sci. 2007 Jul; 98(7):1035-40. Epub 2007 May 04. 1830800
    View PubMed
  155. Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, Lust JA, Greipp PR, Kumar S. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia. 2007 Jul; 21(7):1549-60. Epub 2007 Apr 26. 1834893
    View PubMed
  156. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Leung N, Gastineau DA. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2007 May; 39(10):605-11. 1824567
    View PubMed
  157. Kline M, Donovan K, Wellik L, Lust C, Jin W, Moon-Tasson L, Xiong Y, Witzig TE, Kumar S, Rajkumar SV, Lust JA. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. Leuk Res. 2007 May; 31(5):591-8. 1822510
    View PubMed
  158. Leung N, Dispenzieri A, Lacy MQ, Kumar SK, Hayman SR, Fervenza FC, Cha SS, Gertz MA. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation. Clin J Am Soc Nephrol. 2007 May; 2(3):440-4. Epub 2007 Apr 04. 1818777
    View PubMed
  159. Dingli D, Pacheco JM, Dispenzieri A, Hayman SR, Kumar SK, Lacy MQ, Gastineau DA, Gertz MA. In vivo and in silico studies on single versus multiple transplants for multiple myeloma. Cancer Sci. 2007 May; 98(5):734-9. Epub 2007 Mar 14. 1817572
    View PubMed
  160. Kumar S. Role of autologous stem cell transplantation in multiple myeloma. Curr Hematol Malig Rep. 2007 May; 2(2):121-7. 1997904
    View PubMed
  161. Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, Chung TH, Kim S, Mulligan G, Bryant B, Carpten J, Gertz M, Rajkumar SV, Lacy M, Dispenzieri A, Kyle R, Greipp P, Bergsagel PL, Fonseca R. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007 Apr 1; 67(7):2982-9. 1818627
    View PubMed
  162. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007 Mar; 21(3):529-34. Epub 2007 Jan 18. 1810458
    View PubMed
  163. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S. Transplantation for amyloidosis. Curr Opin Oncol. 2007 Mar; 19(2):136-41. 1810495
    View PubMed
  164. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007 Mar; 82(3):323-41. 1815080
    View PubMed
  165. Bhattacharya R, Patra CR, Verma R, Kumar S, Greipp PR, Mukherjee P. Gold Nanoparticles Inhibit the Proliferation of Multiple Myeloma Cells. Advanced Materials. 2007 Feb; 19(5):711-6. 2199271
  166. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007 Jan 15; 109(2):465-70. Epub 2006 Sep 28. 1802370
    View PubMed
  167. Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, Ishitsuka K, Kumar S, Kumar R, Pandite LN, Hideshima T, Chauhan D, Anderson KC. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A. 2006 Dec 19; 103(51):19478-83. Epub 2006 Dec 12. 1799727
    View PubMed
  168. Timm MM, Kimlinger TK, Haug JL, Kline MP, Greipp PR, Rajkumar SV, Kumar SK. Thymoglobulin targets multiple plasma cell antigens and has in vitro and in vivo activity in multiple myeloma. Leukemia. 2006 Oct; 20(10):1863-9. Epub 2006 Aug 17. 1789265
    View PubMed
  169. Raje N, Kumar S, Hideshima T, Ishitsuka K, Yasui H, Chhetri S, Vallet S, Vonescu E, Shiraishi N, Kiziltepe T, Elford HL, Munshi NC, Anderson KC. Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells. Br J Haematol. 2006 Oct; 135(1):52-61. Epub 2006 Aug 22. 1779706
    View PubMed
  170. Bryce AH, Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Inwards DJ, Yasenchak CA, Kumar SK, Gertz MA. Response to rituximab in patients with type II cryoglobulinemia. Clin Lymphoma Myeloma. 2006 Sep; 7(2):140-4. 1786787
    View PubMed
  171. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006 Aug; 81(8):1047-53. 1775762
    View PubMed
  172. Kimlinger T, Kline M, Kumar S, Lust J, Witzig T, Rajkumar SV. Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma. Haematologica. 2006 Aug; 91(8):1033-40. Epub 2006 Jul 25. 1775794
    View PubMed
  173. Kumar S, Rajkumar SV. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer. 2006 Jul; 42(11):1612-22. Epub 2006 Jun 05. 1779580
    View PubMed
  174. Chng WJ, Ahmann GJ, Henderson K, Santana-Davila R, Greipp PR, Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Rajkumar SV, Lust JA, Kyle RA, Zeldenrust SR, Hayman SR, Fonseca R. Clinical implication of centrosome amplification in plasma cell neoplasm. Blood. 2006 May 1; 107(9):3669-75. Epub 2005 Dec 22. 1760899
    View PubMed
  175. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, Kumar SK, Clark R, Kyle RA, Litzow MR, Inwards DJ, Ansell SM, Micallef IM, Porrata LF, Elliott MA, Johnston PB, Greipp PR, Witzig TE, Zeldenrust SR, Russell SJ, Gastineau D, Gertz Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2006 Apr 15; 107(8):3378-83. Epub 2006 Jan 05. 1758154
    View PubMed
  176. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK. High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Expert Rev Anticancer Ther. 2006 Mar; 6(3):343-60. 1752203
    View PubMed
  177. Kumar S, Raje N, Hideshima T, Ishitsuka K, Podar K, Le Gouille S, Chauhan D, Richardson P, Munshi NC, Anderson K. FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. Br J Haematol. 2006 Mar; 132(6):698-704. 1750502
    View PubMed
  178. Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006 Jan 1; 66(1):184-91. 1744236
    View PubMed
  179. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005 Dec 15; 106(13):4050-3. Epub 2005 Aug 23. 1977482
    View PubMed
  180. Kumar S, Rajkumar SV. Thalidomide and dexamethasone: therapy for multiple myeloma. Expert Rev Anticancer Ther. 2005 Oct; 5(5):759-66. 1743778
    View PubMed
  181. Lacy MQ, Hogan WJ, Gertz MA, Dispenzieri A, Rajkumar SV, Hayman S, Kumar S, Litzow MR, Schroeter AL. Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. Arch Dermatol. 2005 Oct; 141(10):1277-82. 1732132
    View PubMed
  182. Kumar S, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R, Lust JA, Gertz MA, Greipp PR, Witzig TE. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. Journal of Clinical Oncology. 2005 Aug 20; 23(24):5668-74. 1726752
    View PubMed
  183. Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H, Shiraishi N, Chauhan D, Munshi NC, Green SR, Anderson KC. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood. 2005 Aug 1; 106(3):1042-7. 1729930
    View PubMed
  184. Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia. 2005 Aug; 19(8):1466-70. 1724095
    View PubMed
  185. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant. 2004 Sep; 34(6):485-90. 1663575
    View PubMed
  186. Kumar S, Rajkumar SV, Greipp PR, Witzig TE. Cell proliferation of myeloma plasma cells: Comparison of the blood and marrow compartments. Am J Hematol. 2004 Sep; 77(1):7-11. 1662419
    View PubMed
  187. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Kimlinger TK, Greipp PR, Rajkumar SV. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood. 2004 Aug 15; 104(4):1159-65. Epub 2004 May 06. 1657400
    View PubMed
  188. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Wellik LA, Fonseca R, Lust JA, Witzig TE, Kyle RA, Greipp PR, Rajkumar SV. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant. 2004 Aug; 34(3):235-9. 1657329
    View PubMed
  189. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant. 2004 Jul; 34(2):161-7. 1653763
    View PubMed
  190. Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Larson DR, Kyle RA, Greipp PR. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004 Jul; 79(7):867-74. 1653705
    View PubMed
  191. Kumar S, Witzig TE, Rajkumar SV. Thalidomid: current role in the treatment of non-plasma cell malignancies. J Clin Oncol. 2004 Jun 15; 22(12):2477-88. 1649186
    View PubMed
  192. Kumar S, Witzig TE, Dispenzieri A, Lacy MQ, Wellik LE, Fonseca R, Lust JA, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia. 2004 Mar; 18(3):624-7. 1639046
    View PubMed
  193. Raje N, Kumar S, Hideshima T, et al. Combination of the mTOR inhibitor Rapamycin and RevlimidTM(CC-5013) has synergistic activity in multiple myeloma. Blood. 2004. 1677259
    View PubMed
  194. Kumar S, Litzow MR, Rajkumar SV. Effect of allogeneic stem cell transplantation on bone marrow angiogenesis in chronic myelogenous leukemia. Bone Marrow Transplant. 2003 Dec; 32(11):1065-9. 1425173
    View PubMed
  195. Huber MR, Kumar S, Tefferi A. Treatment advances in adult immune thrombocytopenic purpura. Ann Hematol. 2003 Dec; 82(12):723-37. 1429111
    View PubMed
  196. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, Greipp PR, Rajkumar SV. Expression of VEGF and its receptors by myeloma cells. Leukemia. 2003 Oct; 17(10):2025-31. 1420007
    View PubMed
  197. Thompson MA, Witzig TE, Kumar S, Timm MM, Haug J, Fonseca R, Greipp PR, Lust JA, Rajkumar SV. Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. Br J Haematol. 2003 Oct; 123(2):305-8. 1417051
    View PubMed
  198. Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Litzow MR. Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. Leukemia. 2003 Sep; 17(9):1865-70. 1415019
    View PubMed
  199. Kumar S, Kimlinger TK, Lust JA, Donovan K, Witzig TE. Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood. 2003 Aug 1; 102(3):1075-7. Epub 2003 Apr 24. 1405644
    View PubMed
  200. Kumar S, Witzig TE, Greipp PR, Rajkumar SV. Bone marrow angiogenesis and circulating plasma cells in multiple myeloma. Br J Haematol. 2003 Jul; 122(2):272-4. 1404356
    View PubMed
  201. Kumar S, Kamath PS. Acute superior mesenteric venous thrombosis: One disease or two? Am J Gastroenterol. 2003 Jun; 98(6):1299-304. 1396886
    View PubMed
  202. Jatoi A, Kumar S, Sloan JA, Nguyen PL. On appetite and its loss. J Clin Oncol. 2003 May 1; 21(9 Suppl):79s-81s. 1652599
    View PubMed
  203. Kumar S, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc. 2003 May; 78(5):589-98. 1346727
    View PubMed
  204. Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand's syndrome: a single institution experience. Am J Hematol. 2003 Apr; 72(4):243-7. 1328811
    View PubMed
  205. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM, Iturria N, Kumar S, Lust JA, Kyle RA, Greipp PR, Witzig TE. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003 Apr; 17(4):775-9. 1340478
    View PubMed
  206. Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Wellik L, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood. 2003 Mar 1; 101(5):1715-7. 1318915
    View PubMed
  207. Bucheit AD, Kumar S, Grote DM, Lin YK, von Messling V, Cattaneo RB, Fielding AK. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Molecular Therapy: the Journal of the American Society of Gene Therapy. 2003 Jan; 7(1):62-72. 1318614
    View PubMed
  208. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL, Fonseca R, Hayman SR, Lust JA, Kyle RA, Greipp PR, Witzig TE, Rajkumar SV. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc. 2003 Jan; 78(1):34-9. 1317937
    View PubMed
  209. Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Bone marrow angiogenesis in multiple myeloma: effect of therapy. Br J Haematol. 2002 Dec; 119(3):665-71. 1317104
    View PubMed
  210. Kumar S, Wolf RC, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Litzow MR. Omission of day+11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease. Bone Marrow Transplant. 2002 Aug; 30(3):161-5. 1315278
    View PubMed
  211. Porrata LF, Litzow MR, Tefferi A, Letendre L, Kumar S, Geyer SM, Markovic SN. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia. 2002 Jul; 16(7):1311-8. 1314934
    View PubMed
  212. Kumar S, Diehn FE, Gertz MA, Tefferi A. Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. Ann Hematol. 2002 Jun; 81(6):312-9. 1314810
    View PubMed
  213. Kumar S, Witzig TE, Rajkumar SV. Thalidomide as an anti-cancer agent. Journal of Cellular & Molecular Medicine. 2002 Apr-Jun; 6(2):160-74. 1407367
    View PubMed
  214. Kumar S, Menke DM, Dewald GW, Colon-Otero G. Agnogenic myeloid metaplasia associated with Klinefelter syndrome: a case report. Ann Hematol. 2002 Apr; 81(4):215-8. Epub 2002 Mar 07. 1315836
    View PubMed
  215. Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand disease. Mayo Clin Proc. 2002 Feb; 77(2):181-7. 1008102
    View PubMed
  216. Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis. N Engl J Med. 2001 Dec 6; 345(23):1683-8. 1006858
    View PubMed
  217. Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Litzow MR. Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant. 2001 Nov; 28(10):951-6. 1006836
    View PubMed
  218. Tefferi A, Kumar S, Wolf RC, Lacy MQ, Inwards DJ, Gloor JM, Albright RC, Kamath PS, Litzow MR. Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001 Nov; 28(10):997-9. 1006837
    View PubMed
  219. Kumar S, Dispenzieri A, Lacy MQ, Litzow MR, Gertz MA. High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. Bone Marrow Transplant. 2001 Aug; 28(4):381-5. 1004999
    View PubMed
  220. Kumar S, Tefferi A. Spontaneous pneumomediastinum and subcutaneous emphysema complicating bronchiolitis obliterans after allogeneic bone marrow transplantation--case report and review of literature. Ann Hematol. 2001 Jul; 80(7):430-5. 1005616
    View PubMed
  221. Capizzi SA, Kumar S, Huneke NE, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Gastineau DA, Prakash UB, Tefferi A. Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001 Jun; 27(12):1299-303. 1005687
    View PubMed
  222. Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Harmsen WS, Litzow MR. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease. Bone Marrow Transplant. 2001 Jun; 27(11):1133-40. 1014993
    View PubMed
  223. Kumar S, Lacy MQ. 59-year-old man with pelvic pain and hypergammaglobulinemia. Mayo Clin Proc. 2001 Mar; 76(3):311-4. 1003658
    View PubMed
  224. Kumar SK, Goldberg RM. Adjuvant chemotherapy for colon cancer. Curr Oncol Rep. 2001 Mar; 3(2):94-101. 1005125
    View PubMed
  225. Jatoi A, Kumar S, Sloan JA, Nguyen PL. On appetite and its loss. J Clin Oncol. 2000 Aug; 18(15):2930-2. 136699
    View PubMed
  226. Kumar S, Mow BM, Kaufmann SH. Hypercalcemia complicating leukemic transformation of agnogenic myeloid metaplasia-myelofibrosis. Mayo Clin Proc. 1999 Dec; 74(12):1233-7. 125354
    View PubMed
  227. Guleria R, Kumar S, Agarwal S, Prasad L. Renal failure with skeletal abnormalities. Postgrad Med J. 1996; 72:569-570. 1677251
    View PubMed